York spinout Cizzle Biotechnology has undertaken a reverse merger with Bould Opportunities to list on the London Stock Exchange.
Cizzle Biotechnology, a UK-based developer of a blood test to detect lung cancer that was spun out of University of York, has completed a reverse merger with blank cheque company Bould Opportunities and listed on the London Stock Exchange (LSE).
The £21m ($29m) deal marks the first time that a York spinout has listed on LSE. The combined business will operate as Cizzle Biotechnology Holdings.
Founded in 2004 as M&R 971, Cizzle Biotechnology has created a blood test…
